CREGS Launch - Study Insights and First Expert Reactions

In October, the new CREGS study was published - the largest clinical investigation ever conducted on Cerebrolysin^®, involving more than 1.800 patients with acute ischemic stroke.

The highly positive results were presented to a large number of clinicians, where first expert impressions and reactions were collected.

Learn more about the study, its outstanding results, and expert perspectives in the video below.
Watch the video to gain deeper insights into the CREGS study and its clinical relevance!

Cerebrolysin^® - First and only pharmacological agent evidence-based for all acute ischemic stroke patients

• Early and sustained functional recovery
• Effective as stand-alone therapy
• Preserves cognitive functions
• Enhances the effects of recanalization therapy

Confirmed in a global real-world data study involving 1.865 patients

More information you can find here!